Atractylenolide II

Modify Date: 2024-01-02 11:38:39

Atractylenolide II Structure
Atractylenolide II structure
 Common Name Atractylenolide II
CAS Number 73069-14-4 Molecular Weight 232.318
Density 1.1±0.1 g/cm3 Boiling Point 378.0±41.0 °C at 760 mmHg
Molecular Formula C15H20O2 Melting Point N/A
MSDS N/A Flash Point 158.7±25.0 °C

 Use of Atractylenolide II


Atractylenolide II is a sesquiterpene compound isolated from the dried rhizome of Atractylodes macrocephala (Baizhu in Chinese); anti-proliferative activity.IC50 value: 82.3 μM(B16 melanoma cell, 48 h) [1]Target: anticancer natural compoundin vitro: AT-II treatment for 48 h dose-dependently inhibited cell proliferation with an IC(50) of 82.3 μM, and induced G1 phase cell cycle arrest. Moreover, treatment with 75 μM AT-II induced apoptosis. These observations were associated with the decrease of the expression of Cdk2, phosphorylated-Akt, phosphorylated-ERK and Bcl-2, the increase of the expression of phosphorylated-p38, phosphorylated-p53, p21, p27, and activation of caspases-8, -9 and -3. In addition, a chemical inhibitor of p53, PFTα, significantly decreased AT-II-mediated growth inhibition and apoptosis [1]. In B16 and A375 cells, AT-II (20, 40 μm) treatment for 48 h dose-dependently reduced protein expression levels of phospho-STAT3, phospho-Src, as well as STAT3-regulated Mcl-1 and Bcl-xL. Overexpression of a constitutively active variant of STAT3, STAT3C in A375 cells diminished the antiproliferative and apoptotic effects of AT-II [2].in vivo: Daily administration of AT-II (12.5, 25 mg/kg, i.g.) for 14 days significantly inhibited tumor growth in a B16 xenograft mouse model and inhibited the activation/phosphorylation of STAT3 and Src in the xenografts [2].

 Names

Name 2-atractylenolide
Synonym More Synonyms

 Atractylenolide II Biological Activity

Description Atractylenolide II is a sesquiterpene compound isolated from the dried rhizome of Atractylodes macrocephala (Baizhu in Chinese); anti-proliferative activity.IC50 value: 82.3 μM(B16 melanoma cell, 48 h) [1]Target: anticancer natural compoundin vitro: AT-II treatment for 48 h dose-dependently inhibited cell proliferation with an IC(50) of 82.3 μM, and induced G1 phase cell cycle arrest. Moreover, treatment with 75 μM AT-II induced apoptosis. These observations were associated with the decrease of the expression of Cdk2, phosphorylated-Akt, phosphorylated-ERK and Bcl-2, the increase of the expression of phosphorylated-p38, phosphorylated-p53, p21, p27, and activation of caspases-8, -9 and -3. In addition, a chemical inhibitor of p53, PFTα, significantly decreased AT-II-mediated growth inhibition and apoptosis [1]. In B16 and A375 cells, AT-II (20, 40 μm) treatment for 48 h dose-dependently reduced protein expression levels of phospho-STAT3, phospho-Src, as well as STAT3-regulated Mcl-1 and Bcl-xL. Overexpression of a constitutively active variant of STAT3, STAT3C in A375 cells diminished the antiproliferative and apoptotic effects of AT-II [2].in vivo: Daily administration of AT-II (12.5, 25 mg/kg, i.g.) for 14 days significantly inhibited tumor growth in a B16 xenograft mouse model and inhibited the activation/phosphorylation of STAT3 and Src in the xenografts [2].
Related Catalog
References

[1]. Ye Y, et al. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol. 2011 Jun 14;136(1):279-82.

[2]. Fu XQ, et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol. 2014 Nov;23(11):855-7.

 Chemical & Physical Properties

Density 1.1±0.1 g/cm3
Boiling Point 378.0±41.0 °C at 760 mmHg
Molecular Formula C15H20O2
Molecular Weight 232.318
Flash Point 158.7±25.0 °C
Exact Mass 232.146332
PSA 26.30000
LogP 3.61
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.535
Storage condition -20°C

 Precursor & DownStream

Precursor  2

DownStream  0

 Synonyms

(4aS,8aR,9aS)-3,8a-dimethyl-5-methylidene-4a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2(4H)-one
AtractylenolideII
(4aS,8aR,9aS)-3,8a-Dimethyl-5-methylene-4a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2(4H)-one
Naphtho[2,3-b]furan-2(4H)-one, 4a,5,6,7,8,8a,9,9a-octahydro-3,8a-dimethyl-5-methylene-, (4aS,8aR,9aS)-
(4aS,8aR,9aS)-4a,5,6,7,8,8a,9,9a-Octahydro-3,8a-dimethyl-5-methylenenaphtho[2,3-b]furan-2(4H)-one
Eudesmanolide
ASTEROLIDE
Atractylon-Autoxidationsprodukt A
Atractylenolide II
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Atractylenolide II suppliers

Price: $244/10mM*1mLinDMSO

Reference only. check more Atractylenolide II price

Related Compounds: More...
Atractylenolide III
73030-71-4
atractylenolide IV
147396-00-7
Atractylenolide I
73069-13-3
indium(ii) chloride
13465-11-7
Urotensin II-Related Peptide (human, mouse, rat) trifluoroacetate salt
342878-90-4
cobalt(II)(glycinate)(1+)
100293-84-3
lead(ii) tartrate
815-84-9
lead(II) carbonate
790616-79-4
ZINC(II)TETRANITROPHTHALOCYANINE
100043-01-4
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
(3S)-3-{[(benzyloxy)carbonyl]amino}-3-(1H-pyrrol-2-yl)propanoic acid
2137090-41-4
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
tert-Butyl-DL-alanine
1375289-11-4
4-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-ethylbenzenesulfonamide
849349-65-1
Chemsrc provides Atractylenolide II(CAS#:73069-14-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Atractylenolide II are included as well.>> amp version: Atractylenolide II

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved